Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trial
Briefly

from Fast Company4 months ago
Novo Nordisk's Amycretin pill shows potential for significantly faster weight loss compared to Wegovy, losing 13.1% of body weight in just three months according to early trial data.
Fast Companyhttps://www.fastcompany.com/91188837/the-highly-anticipated-new-obesity-pill-shows-the-potential-for-greater-and-faster-weight-loss-than-wegovy
In the latest clinical trials, participants using Amycretin lost over twice the amount of weight compared to those on Wegovy, indicating a possible shift in obesity treatment.
Fast Companyhttps://www.fastcompany.com/91188837/the-highly-anticipated-new-obesity-pill-shows-the-potential-for-greater-and-faster-weight-loss-than-wegovy
The new obesity pill provides a daily oral alternative to injected drugs like Ozempic and Wegovy, appealing to a broader segment of consumers seeking weight loss solutions.
Fast Companyhttps://www.fastcompany.com/91188837/the-highly-anticipated-new-obesity-pill-shows-the-potential-for-greater-and-faster-weight-loss-than-wegovy
Amycretin’s trials revealed mild gastrointestinal side effects similar to other weight-loss drugs, presenting a common challenge for pharmaceutical innovations in obesity management.
Fast Companyhttps://www.fastcompany.com/91188837/the-highly-anticipated-new-obesity-pill-shows-the-potential-for-greater-and-faster-weight-loss-than-wegovy
Read at Fast Company
#obesity-treatment #pharmaceuticals #clinical-trials #novo-nordisk #weight-loss
[
|
]